Selected research
Industry Research
Epidermolysis Bullosa Therapeutics Industry Research Report 2026
Market perspective
The global Epidermolysis Bullosa Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Epidermolysis Bullosa Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Epidermolysis Bullosa Therapeutics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Epidermolysis Bullosa Therapeutics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Epidermolysis Bullosa Therapeutics include Birken AG, Fibrocell Science, Inc., GlaxoSmithKline Plc, InMed Pharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V., RegeneRx Biopharmaceuticals, Inc., Scioderm, Inc. and Stratatech Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Epidermolysis Bullosa Therapeutics market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Epidermolysis Bullosa Therapeutics Market by Company
Birken AG
Fibrocell Science, Inc.
GlaxoSmithKline Plc
InMed Pharmaceuticals Inc.
Karus Therapeutics Limited
ProQR Therapeutics N.V.
RegeneRx Biopharmaceuticals, Inc.
Scioderm, Inc.
Stratatech Corporation
TWi Pharmaceuticals, Inc.
WAVE Life Sciences Ltd.
Epidermolysis Bullosa Therapeutics Segment by Type
INM-750
ICX-RHY
FCX-007
EB-201
Others
Epidermolysis Bullosa Therapeutics Segment by Application
Clinic
Hospital
Others
Epidermolysis Bullosa Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epidermolysis Bullosa Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Epidermolysis Bullosa Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epidermolysis Bullosa Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Epidermolysis Bullosa Therapeutics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Epidermolysis Bullosa Therapeutics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Epidermolysis Bullosa Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- INM-750
- ICX-RHY
- FCX-007
- EB-201
- Others
Applications
- Clinic
- Hospital
- Others
Companies covered
- Birken AG
- Fibrocell Science, Inc.
- GlaxoSmithKline Plc
- InMed Pharmaceuticals Inc.
- Karus Therapeutics Limited
- ProQR Therapeutics N.V.
- RegeneRx Biopharmaceuticals, Inc.
- Scioderm, Inc.
- Stratatech Corporation
- TWi Pharmaceuticals, Inc.
- WAVE Life Sciences Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Epidermolysis Bullosa Therapeutics Market Size (2021-2032)
- 2.2.2 Global Epidermolysis Bullosa Therapeutics Sales (2021-2032)
- 2.2.3 Global Epidermolysis Bullosa Therapeutics Market Average Price (2021-2032)
- 2.3 Epidermolysis Bullosa Therapeutics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 INM-750
- 2.3.3 ICX-RHY
- 2.3.4 FCX-007
- 2.3.5 EB-201
- 2.3.6 Others
- 2.4 Epidermolysis Bullosa Therapeutics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Epidermolysis Bullosa Therapeutics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Epidermolysis Bullosa Therapeutics Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Epidermolysis Bullosa Therapeutics Revenue of Manufacturers (2021-2026)
- 3.4 Global Epidermolysis Bullosa Therapeutics Average Price by Manufacturers (2021-2026)
- 3.5 Global Epidermolysis Bullosa Therapeutics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Epidermolysis Bullosa Therapeutics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Epidermolysis Bullosa Therapeutics, Product Type & Application
- 3.8 Global Manufacturers of Epidermolysis Bullosa Therapeutics, Established Date
- 3.9 Global Epidermolysis Bullosa Therapeutics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Birken AG
- 4.1.1 Birken AG Company Information
- 4.1.2 Birken AG Business Overview
- 4.1.3 Birken AG Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Birken AG Epidermolysis Bullosa Therapeutics Product Portfolio
- 4.1.5 Birken AG Recent Developments
- 4.2 Fibrocell Science, Inc.
- 4.2.1 Fibrocell Science, Inc. Company Information
- 4.2.2 Fibrocell Science, Inc. Business Overview
- 4.2.3 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
- 4.2.5 Fibrocell Science, Inc. Recent Developments
- 4.3 GlaxoSmithKline Plc
- 4.3.1 GlaxoSmithKline Plc Company Information
- 4.3.2 GlaxoSmithKline Plc Business Overview
- 4.3.3 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Product Portfolio
- 4.3.5 GlaxoSmithKline Plc Recent Developments
- 4.4 InMed Pharmaceuticals Inc.
- 4.4.1 InMed Pharmaceuticals Inc. Company Information
- 4.4.2 InMed Pharmaceuticals Inc. Business Overview
- 4.4.3 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
- 4.4.5 InMed Pharmaceuticals Inc. Recent Developments
- 4.5 Karus Therapeutics Limited
- 4.5.1 Karus Therapeutics Limited Company Information
- 4.5.2 Karus Therapeutics Limited Business Overview
- 4.5.3 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Product Portfolio
- 4.5.5 Karus Therapeutics Limited Recent Developments
- 4.6 ProQR Therapeutics N.V.
- 4.6.1 ProQR Therapeutics N.V. Company Information
- 4.6.2 ProQR Therapeutics N.V. Business Overview
- 4.6.3 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Product Portfolio
- 4.6.5 ProQR Therapeutics N.V. Recent Developments
- 4.7 RegeneRx Biopharmaceuticals, Inc.
- 4.7.1 RegeneRx Biopharmaceuticals, Inc. Company Information
- 4.7.2 RegeneRx Biopharmaceuticals, Inc. Business Overview
- 4.7.3 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
- 4.7.5 RegeneRx Biopharmaceuticals, Inc. Recent Developments
- 4.8 Scioderm, Inc.
- 4.8.1 Scioderm, Inc. Company Information
- 4.8.2 Scioderm, Inc. Business Overview
- 4.8.3 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
- 4.8.5 Scioderm, Inc. Recent Developments
- 4.9 Stratatech Corporation
- 4.9.1 Stratatech Corporation Company Information
- 4.9.2 Stratatech Corporation Business Overview
- 4.9.3 Stratatech Corporation Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Stratatech Corporation Epidermolysis Bullosa Therapeutics Product Portfolio
- 4.9.5 Stratatech Corporation Recent Developments
- 4.10 TWi Pharmaceuticals, Inc.
- 4.10.1 TWi Pharmaceuticals, Inc. Company Information
- 4.10.2 TWi Pharmaceuticals, Inc. Business Overview
- 4.10.3 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
- 4.10.5 TWi Pharmaceuticals, Inc. Recent Developments
- 4.11 WAVE Life Sciences Ltd.
- 4.11.1 WAVE Life Sciences Ltd. Company Information
- 4.11.2 WAVE Life Sciences Ltd. Business Overview
- 4.11.3 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Product Portfolio
- 4.11.5 WAVE Life Sciences Ltd. Recent Developments
5 Global Epidermolysis Bullosa Therapeutics Market Scenario by Region
- 5.1 Global Epidermolysis Bullosa Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Epidermolysis Bullosa Therapeutics Sales by Region: 2021-2032
- 5.2.1 Global Epidermolysis Bullosa Therapeutics Sales by Region: 2021-2026
- 5.2.2 Global Epidermolysis Bullosa Therapeutics Sales by Region: 2027-2032
- 5.3 Global Epidermolysis Bullosa Therapeutics Revenue by Region: 2021-2032
- 5.3.1 Global Epidermolysis Bullosa Therapeutics Revenue by Region: 2021-2026
- 5.3.2 Global Epidermolysis Bullosa Therapeutics Revenue by Region: 2027-2032
- 5.4 North America Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country
- 5.4.1 North America Epidermolysis Bullosa Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Epidermolysis Bullosa Therapeutics Sales by Country (2021-2032)
- 5.4.3 North America Epidermolysis Bullosa Therapeutics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country
- 5.5.1 Europe Epidermolysis Bullosa Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Epidermolysis Bullosa Therapeutics Sales by Country (2021-2032)
- 5.5.3 Europe Epidermolysis Bullosa Therapeutics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Epidermolysis Bullosa Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Epidermolysis Bullosa Therapeutics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Epidermolysis Bullosa Therapeutics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country
- 5.7.1 South America Epidermolysis Bullosa Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Epidermolysis Bullosa Therapeutics Sales by Country (2021-2032)
- 5.7.3 South America Epidermolysis Bullosa Therapeutics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Epidermolysis Bullosa Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Epidermolysis Bullosa Therapeutics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Epidermolysis Bullosa Therapeutics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Epidermolysis Bullosa Therapeutics Sales by Type (2021-2032)
- 6.1.1 Global Epidermolysis Bullosa Therapeutics Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2021-2032)
- 6.2 Global Epidermolysis Bullosa Therapeutics Revenue by Type (2021-2032)
- 6.2.1 Global Epidermolysis Bullosa Therapeutics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2021-2032)
- 6.3 Global Epidermolysis Bullosa Therapeutics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Epidermolysis Bullosa Therapeutics Sales by Application (2021-2032)
- 7.1.1 Global Epidermolysis Bullosa Therapeutics Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2021-2032)
- 7.2 Global Epidermolysis Bullosa Therapeutics Revenue by Application (2021-2032)
- 7.2.1 Global Epidermolysis Bullosa Therapeutics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application (2021-2032)
- 7.3 Global Epidermolysis Bullosa Therapeutics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Epidermolysis Bullosa Therapeutics Value Chain Analysis
- 8.1.1 Epidermolysis Bullosa Therapeutics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Epidermolysis Bullosa Therapeutics Production Mode & Process
- 8.2 Epidermolysis Bullosa Therapeutics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Epidermolysis Bullosa Therapeutics Distributors
- 8.2.3 Epidermolysis Bullosa Therapeutics Customers
9 Global Epidermolysis Bullosa Therapeutics Analyzing Market Dynamics
- 9.1 Epidermolysis Bullosa Therapeutics Industry Trends
- 9.2 Epidermolysis Bullosa Therapeutics Industry Drivers
- 9.3 Epidermolysis Bullosa Therapeutics Industry Opportunities and Challenges
- 9.4 Epidermolysis Bullosa Therapeutics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst